Dong-A Faces Price Hit As Korea Ups Fight Against Illegal Rebates
Executive Summary
In its ongoing clamp down against illegal rebate activities in the domestic pharmaceutical industry, South Korea cuts prices of Dong-A ST’s drugs. This follows recent punitive measures against Novartis' Korean subsidiary.